Irritant antineoplastic drugs
Drugs classified as “Irritant” in at least one of the three guidelines. Each guideline column shows the class it assigns.
| ONS/ASCO 2025 | ESMO-EONS 2012 | JSCN/JSMO/JASPO 2024 | |
|---|---|---|---|
| Bleomycin | — | Nonvesicant | Irritant |
| Carboplatin | Irritant with vesicant properties | Irritant | Irritant |
| Carmustine | Irritant with vesicant properties | Irritant | — |
| Cisplatin | Irritant with vesicant properties | Irritant | — |
| Cyclophosphamide | — | Nonvesicant | Irritant |
| Dacarbazine | — | Irritant | — |
| Daunorubicin (liposomal) | — | Irritant | — |
| Doxorubicin (liposomal) | — | Irritant | Irritant |
| Etoposide | Irritant with vesicant properties | Irritant | — |
| Fluorouracil | — | Irritant | Irritant |
| Gemtuzumab ozogamicin | — | — | Irritant |
| Ifosfamide | — | Irritant | Irritant |
| Irinotecan | — | Irritant | Irritant |
| Ixabepilone | — | Irritant | — |
| Melphalan | — | Irritant | — |
| Mitoxantrone | Irritant with vesicant properties | VesicantIrritant | Vesicant |
| Oxaliplatin | Irritant with vesicant properties | Irritant | Vesicant |
| Streptozocin | — | Irritant | — |
| Teniposide | — | Irritant | — |
| Topotecan | — | Irritant | Irritant |